Plasma PTX3 levels in sickle cell disease patients, during vaso occlusion and acute chest syndrome (data from Saudi population)

References

• Musa BO, Onyemelukwe GC, Hambolu JO, Mamman AI, Isa AH. Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis. Clin Vaccine Immunol. 2010;17(4):602–8.
   PubMed Web of Science ®Google Scholar
• Jastaniah W. Epidemiology of sickle cell disease in Saudi Arabia. Ann Saudi Med. 2011;31(3):289–93.
   PubMed Web of Science ®Google Scholar
• Alabdulaali MK. Sickle cell disease patients in eastern province of Saudi Arabia suffer less severe acute chest syndrome than patients with African haplotypes. Ann Thorac Med. 2007;2:158–62.
   PubMedGoogle Scholar
• Serjeant GR, Ceulaer CD, Lethbridge R, Morris J, Singhal A, Thomas PW. The painful crisis of homozygous sickle cell disease: clinical features. Br J Haematol. 1994;87(3):586–91.
   PubMed Web of Science ®Google Scholar
• Platt OS, Harington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al. Pain in sickle cell disease. Rates and risk factors.N Engl J Med. 1991;325(1):11–6.
   PubMed Web of Science ®Google Scholar
• Baum KF, Dunn DT, Maude GH, Serjeant GR. The painful crisis of homozygous sickle cell disease: clinical features. Br J Haematol. 1994;87(3):586–91.
   PubMed Web of Science ®Google Scholar
• Francis RB, Johnson CS. Vascular occlusion in sickle cell disease: current concepts and unanswered questions. Blood. 1991;77(7):1405–14.
   PubMed Web of Science ®Google Scholar
• Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle cell disease pathophysiology. Blood. 1991;77(2):214–37.
   PubMed Web of Science ®Google Scholar
• Platt OS. Easing the suffering caused by sickle cell disease. N Engl J Med. 1994;330(11):783–4.
   PubMed Web of Science ®Google Scholar
• Powars DR. Sickle cell anemia and major organ failure. Hemoglobin. 1990;14(6):573–98.
   PubMed Web of Science ®Google Scholar
• Ballas SK, Mohandas N. Pathophysiology of vaso-occlusion. Hematol Oncol North Am. 1996;10(6):1221–39.
   PubMed Web of Science ®Google Scholar
• Duits AJ, Schnog JB, Lard LR, Saleh AW, Rojer RA. Elevated IL-8 levels during sickle cell crisis. Eur J Haematol. 1998;61(5):302–5.
   PubMed Web of Science ®Google Scholar
• Krishnam S, Setty Y, Betal SG, Vijender V, Rao K, Dampier C, et al. Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vaso-occlusive crisis. Br J Haematol. 2010;148(5):797–804.
   PubMed Web of Science ®Google Scholar
• Adewoye AH, Klings ES, Farber HW, Palaima E, Bausero MA, McMahon L, et al. Sickle cell vaso-occlusive crisis induces the release of serum heat shock protein-70. Am J Hematol. 2005;78(3):240–2.
   PubMed Web of Science ®Google Scholar
• Styles LA, Aarsman AJ, Vickinsky EP, Kuypres FA. Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. Blood. 2000;96(9):3276–8.
   PubMed Web of Science ®Google Scholar
• Ballas SK, Files B, Jones LL, Benjamin L, Swerdlow P, Hilliard L, et al. Secretory phospholipase A2 levels in sickle cell disease and acute chest syndrome. Hemoglobin. 2006;30(2):165–70.
   PubMed Web of Science ®Google Scholar
• Styles LA, Wager CG, Labotka RJ, Smith-Whitley K, Thompson A, Lane PA, et al. Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE). Br J Haematol. 2012;157(5):627–36.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008;28(1):1–13.
   PubMed Web of Science ®Google Scholar
• Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102(6):636–41.
   PubMed Web of Science ®Google Scholar
• Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110(16):2349–54.
   PubMed Web of Science ®Google Scholar
• Rezaei-Kalantari H. How I treat … sickle cell anemia: current therapies. Rev Med Liege. 2001;56(10):671–5.
   PubMedGoogle Scholar
• Lottenberg R, Hassell KL. An evidence-based approach to the treatment of adults with sickle cell disease. ASH Education Book 2005;1:58–65.
   Google Scholar
• Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001;29(7):1404–7.
   PubMed Web of Science ®Google Scholar
• Kunes P, Holubcova Z, Kolackova M, Krejeski J. Pentraxin 3: an endogenous modulator of the inflammatory response. Mediators Inflamm. 2012; 2012(article ID 920517): 10.
   Web of Science ®Google Scholar
• Deban L, Russo RC, Sironi M, Moalli F, Scanziani M, Zambelli V, et al. Regulation of leucocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010;11(4):328–34.
   PubMed Web of Science ®Google Scholar
• Nur E, van Beers EJ, Martina S, Cuccovillo I, Otten HM, Schnog JJ, et al. Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis. Blood Cells Mol Dis. 2011;46(3):189–94.
   PubMed Web of Science ®Google Scholar
• Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative study of sickle cell disease. Blood. 1997;89(5):1787–92.
   PubMed Web of Science ®Google Scholar
• Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342(2):83–9.
   PubMed Web of Science ®Google Scholar
• Han B, Mura M, Andrade CF, Okutani D, Lodyga M, dos Santos CC, et al. TNFα-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK. J Immunol. 2005;175:8303–11.
   PubMed Web of Science ®Google Scholar
• Mauri T, Coppadoro A, Bellani G, Bambino M, Patroniti N, Peri G, et al. Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med. 2008;36(8):2302–8.
   PubMed Web of Science ®Google Scholar
• Bargoma EM, Mitsuyoshi JK, Larkin SK, Styles LA, Kuypers FA, Test ST. Serum C-reactive protein parallels secretory phospholipase A2 in sickle cell disease patients with vaso-occlusive crisis or acute chest syndrome. Blood. 2005;105:3384–5.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Bottazzi B, Mantovani A. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol. 2003;33(2):465–73.
   PubMed Web of Science ®Google Scholar
• Han B, Haitsma JJ, Zhang Y, Bai X, Rubacha M, Keshavjee S, et al. Long pentraxin PTX3 deficiency worsens LPS-induced acute lung injury. Intensive Care Med. 2011;37:334–42.
   PubMed Web of Science ®Google Scholar